BPC-157 and the FDA: Where Things Actually Stand
The regulatory position on BPC-157 changed twice in 2026, and almost everything written about it online is out of date, overstated in one direction or the other, or both. Some sites still describe it as banned. Others announced in July that it had been approved. Neither is right.
This page sets out what happened, in order, with the parts that are decided separated from the parts that are not. It is the most consequential page in this cluster, so it is written conservatively on purpose. The evidence page covers the science, which is a different question and moved a great deal less.
The short answer
BPC-157 is not an FDA-approved drug. It has never been approved, for any use, in the United States.
Its standing in the compounding system — the separate framework that governs what a pharmacy may make for an individual patient — is unsettled and is actively being revisited. A federal advisory committee recommended in July 2026 that it be allowed. That recommendation has not yet been turned into a rule, and until it is, nothing about its status has formally changed.
Everything below is the detail behind those two paragraphs.
How BPC-157 came to be restricted
Compounding pharmacies operating under section 503A of the Federal Food, Drug, and Cosmetic Act may use bulk drug substances that appear on an FDA list. To evaluate substances nominated for that list, the FDA maintains an interim categorized list. Category 1 substances may be used while evaluation continues. Category 2 substances are those the agency has identified as raising significant safety risks, and a pharmacy may not compound with them.
BPC-157 was placed in Category 2 alongside a group of other peptides, which is the origin of the widespread claim that it was banned.
That placement is why BPC-157 has been sold almost entirely through the research chemical market, labeled for research use only. Material sold that way is not a medicine, is not made to pharmaceutical standards, and is not verified for identity or purity.
April 2026: removal from Category 2
In April 2026 the FDA removed twelve peptide substances from Category 2 of the interim 503A bulk substances list. BPC-157 was among them, as were KPV and TB-500.
Two things about that removal are consistently misreported.
It was not a safety finding. The removals followed the parties who had nominated those substances withdrawing their nominations. The agency was not announcing that it had reconsidered the risks and found them acceptable. It was closing out nominations that no longer had anyone behind them.
It did not authorize anything. Coming off Category 2 does not put a substance on the 503A Bulks List, and it is the Bulks List that permits compounding. A substance that is on neither is simply not covered, which is not the same as being permitted.
Sites that reported the April removal as a legalization got this wrong, and some of them are still wrong.
July 2026: the advisory committee vote
On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee met to consider six peptides for inclusion on the 503A Bulks List. It voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted against Emideltide, the substance also known as DSIP.
The margins are part of the story. BPC-157, KPV and TB-500 each passed by eight votes to six, with one abstention. FDA staff had recommended against inclusion before the committee voted the other way.
So the committee's recommendation is real, and it is narrow, and it runs contrary to the agency's own reviewers. That is an unusual combination, and it is a poor foundation for anyone claiming the matter is settled.
What still has to happen
The committee advises. It does not decide.
Formal addition to the 503A Bulks List requires notice-and-comment rulemaking: the FDA proposes a rule, the public comments, the agency responds and issues a final rule. As of September 2026 that process has not been completed for any of the six peptides.
Until it is completed, the position is exactly what it was: BPC-157 is not FDA-approved, and it is not on the list of substances approved for compounding. The direction of travel has shifted. The rule has not.
What we will and will not say about this
We will say that the FDA's position on BPC-157 is unsettled and under active reconsideration, and that a federal advisory committee has recommended a change. That is true and it is useful for a reader trying to understand a confusing situation.
We will not say that BPC-157 is approved, because it is not. We will not say that compounding it is settled law, because that is precisely what has not been settled. We will not describe any preparation of it as equivalent to or interchangeable with an approved medication, because no approved medication containing it exists to compare it to. And we will not treat the research-use-only market as an alternative route, because material sold that way is not a medicine and we would not put a patient on it.
If the rulemaking completes, this page will change. Until then it says what is known.
Frequently asked questions
No. It has never been approved in the United States for any use, and the 2026 developments did not change that. Approval and compounding eligibility are two different systems, and BPC-157 is currently outside both.
Its regulatory status is unsettled. It is not an approved drug, and it is not on the FDA's 503A Bulks List that governs pharmacy compounding. An advisory committee has recommended adding it, and the rulemaking that would do so has not been completed. This is a description of regulatory status, not legal advice.
It removed twelve peptide substances, BPC-157 among them, from Category 2 of the interim 503A list. The removals followed the nominators withdrawing their nominations. It was not a safety determination and it did not authorize compounding.
The Pharmacy Compounding Advisory Committee recommended six peptides, including BPC-157, for the 503A Bulks List. The vote was eight to six with one abstention, and it went against FDA staff's own recommendation. A recommendation is advice to the agency, not a decision by it.
Not on the strength of what has happened so far. Nothing in the April removal or the July vote put BPC-157 on the Bulks List, and that listing is what the compounding framework turns on.
Because most of it is sold as a research chemical rather than as a medicine, outside the framework that governs drugs. Products labeled for research use only carry no assurance of identity, purity or content, and buying one is not the same as being prescribed something.
Where this fits in your plan
If you came here to find out whether you can get BPC-157, the answer is that the picture is genuinely in motion and we will not pretend otherwise. Read the evidence page as well, because the regulatory question and the does-it-work question have different answers and both matter. The peptide therapy overview explains how we handle a category where the rules keep moving.
We measure first. Then we act.
References
- FDA. Interim policy on compounding using bulk drug substances under section 503A of the Federal Food, Drug, and Cosmetic Act — categories 1, 2 and 3.
- FDA. Removal of twelve substances from Category 2 of the 503A interim list, April 2026.
- FDA Pharmacy Compounding Advisory Committee. Meeting materials and voting record, 23–24 July 2026.
- FDA. Bulk drug substances that can be used in compounding under section 503A — final rule and current list.
- 21 U.S.C. § 353a — Pharmacy compounding.
- Back toBPC-157
- BPC-157 evidenceAlmost all BPC-157 research is in rodents. The human trials are few, small and mostly old. What the record actually contains, and what it does not.Read
- BPC-157 and gut healthThe gut is where BPC-157 research started and where it is strongest. It is also still preclinical, with no approved indication. An honest look.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.